Breaking News Instant updates and real-time market news.

BMRN

BioMarin

$97.84

1.79 (1.86%)

, ESALY

Eisai

$0.00

(0.00%)

04:55
12/04/18
12/04
04:55
12/04/18
04:55

American Epilepsy Society to hold annual meeting

72nd Annual Meeting of AES will be held in New Orleans, LA on November 30-December 4.

BMRN

BioMarin

$97.84

1.79 (1.86%)

ESALY

Eisai

$0.00

(0.00%)

EVGN

Evogene

$2.59

(0.00%)

IART

Integra LifeSciences

$53.72

0.07 (0.13%)

INSY

Insys Therapeutics

$5.77

-0.24 (-3.99%)

LIVN

LivaNova

$102.32

1.14 (1.13%)

MNK

Mallinckrodt

$24.16

0.36 (1.51%)

MDT

Medtronic

$98.73

1.21 (1.24%)

NVS

Novartis

$91.55

0.03 (0.03%)

OVID

Ovid Therapeutics

$4.09

0.02 (0.49%)

RICOY

Ricoh

$0.00

(0.00%)

SUPN

Supernus

$48.83

1.51 (3.19%)

WTKWY

Wolters Kluwer

$0.00

(0.00%)

  • 12

    Dec

BMRN BioMarin
$97.84

1.79 (1.86%)

10/23/18
ADAM
10/23/18
NO CHANGE
Target $116
ADAM
Buy
BioMarin price target raised to $116 from $113 at Canaccord
Canaccord analyst Michelle Gilson raised her price target on BioMarin to $116 from $113 to reflect the talazoparib milestone and stronger Palynziq launch. She also believes the ValRox study in hemophilia A is still underappreciated and she sees an accelerated filing in the second half of 2019. Gilson reiterated her Buy rating on BioMarin shares.
10/26/18
JEFF
10/26/18
NO CHANGE
Target $125
JEFF
Buy
BioMarin risk/reward favorable into clinical catalysts, says Jefferies
Jefferies analyst Eun Yang keeps a Buy rating on BioMarin with a $125 price target following the company's Q3 results. With currently marketed products providing a $90 per share valuation floor, the risk/reward for BioMarin shares is favorable into multiple clinical catalysts in 2019-2020, which support potential regulatory approval of three new products, Yang tells investors in a post-earnings research note. She points out that BioMarin beat on Q3 product sales and non-GAAP net income while maintains its fiscal 2018 guidance.
11/14/18
JPMS
11/14/18
DOWNGRADE
Target $11
JPMS
Neutral
JPMorgan downgrades Sangamo to Neutral on 'growing skepticism'
JPMorgan analyst Eric Joseph downgraded Sangamo Therapeutics (SGMO) to Neutral from Overweight and lowered his price target for the shares to $11 from $35. Following the company's Q3 results, the analyst has "growing skepticism" about its lead development programs and "their potential for value creation over the foreseeable future." Visibility into the initial efficacy of the SB-525 / Hemophilia A program "continues to elude, now with indefinite timelines," Joseph tells investors in a research note. With relatively slower recruitment to date, the analyst struggles to see how SB-525 closes ground with the two later-stage competitor FVIII gene therapy programs from BioMarin (BMRN) and Spark Therapeutics (ONCE).
12/03/18
PIPR
12/03/18
NO CHANGE
PIPR
Overweight
Regeneron's REGN1979 'best in show' thus far at ASH, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond calls Regeneron Pharmaceuticals' (REGN) REGN1979 the "best in show" thus far at this year's American Society of Hematology meeting. The analyst says this weekend's updates were largely consistent with his expectations except for the "overwhelmingly impressive data" from REGN1979 in relapsed or refractory follicular lymphoma. This asset could serve as a "significant value driver" for Regeneron shares and the stock is likely to be up sharply today, Raymond tells investors in a research note. He adds that REGN1979 is currently not in his Regeneron model. Following the weekend's updates the analyst keeps Overweight ratings on BioMarin (BMRN) and Regeneron and a Neutral rating on Celgene (CELG).
ESALY Eisai
$0.00

(0.00%)

07/06/18
MSCO
07/06/18
NO CHANGE
Target $369
MSCO
Overweight
Biogen likely to be up 5%-10% on positive Alzheimer's data, says Morgan Stanley
Morgan Stanley analyst Matthew Harrison said the fact that Eisai (ESALY) and Biogen's (BIIB) BAN2401 trial achieved positive topline results at an 18 month landmark analysis is a "clear positive" for the perception of aducanumab and he expects Biogen's shares to be up 5% to over 10% following the news. Harrison added that he would expect full data to be reported at the CTAD meeting in October as he thinks the AAIC meeting coming up in late July is too close. He keeps an Overweight rating and $369 price target on Biogen shares.
07/06/18
NOMU
07/06/18
UPGRADE
NOMU
Buy
Eisai upgraded to Buy from Neutral at Nomura Instinet
07/10/18
MZHO
07/10/18
NO CHANGE
MZHO
Buy
Biogen, Eisai not sharing details on BAN2401 presentation at AAIC, says Mizuho
After Biogen (BIIB) and partner Eisai's (ESALY) recent announcement that BAN2401 demonstrated statistically significant slowing in clinical decline and reduction of amyloid beta accumulation in a trial of Alzheimer's patients, Mizuho analyst Salim Syed said he has checked with both companies and neither is divulging any details about what sort of data on the trial will be shared at the upcoming AAIC meeting. He maintains a Buy rating and $423 price target on Biogen shares.
08/28/18
PIPR
08/28/18
NO CHANGE
PIPR
Overweight
Piper says Biogen PRIME data has little to change minds of bulls or bears
After Biogen (BIIB) and Eisai (ESALY) announced another year's worth of long term extension data from their ongoing PRIME Phase 1b study of aducanumab, Piper Jaffray analyst Christopher Raymond said he sees little in the release to change the minds of either A-beta bulls or A-beta bears. Raymond, who continues to look toward a full Phase 3 data read-out in early 2020 as the key event for aducanumab, keeps an Overweight rating on Biogen shares.
EVGN Evogene
$2.59

(0.00%)

IART Integra LifeSciences
$53.72

0.07 (0.13%)

11/01/18
CANT
11/01/18
NO CHANGE
Target $54
CANT
Neutral
Integra LifeSciences price target lowered to $54 from $59 at Cantor Fitzgerald
Cantor Fitzgerald analyst Craig Bijou lowered his price target for Integra LifeSciences to $54 after the company's Q3 revenue missed expectations. The analyst sees lower 2018 organic growth and believes Integra's 2019 growth is likely to hit the low-end of its long-term target. Bijou maintains a Neutral rating on the shares.
10/31/18
PIPR
10/31/18
NO CHANGE
PIPR
Overweight
Piper says Integra long-term prospects intact despite 'concerning' guidance
Piper Jaffray analyst Matt O'Brien noted that Integra LifeSciences lowered FY18 sales guidance by $13M at the midpoint following a Q3 revenue shortfall that was blamed on further year-over-year declines in Ortho Extremities and a weaker than expected Codman performance outside of the U.S. While the headwinds are "frustrating," O'Brien still sees "a lot to like" about the margin and cash flow improvements and top-line outlook for the business. He reiterates an Overweight rating on Integra shares.
10/31/18
10/31/18
NO CHANGE

Integra LifeSciences reports Q3 adjusted EPS 59c, consensus 59c
Reports Q3 revenue $365.9M, consensus $370.41M.
11/27/18
UBSW
11/27/18
INITIATION
UBSW
Neutral
Integra LifeSciences initiated with a Neutral at UBS
UBS analyst Matthew Taylor initiated Integra LifeSciences with a Neutral rating and $58 price target.
INSY Insys Therapeutics
$5.77

-0.24 (-3.99%)

03/09/18
PIPR
03/09/18
DOWNGRADE
Target $4
PIPR
Underweight
Insys Therapeutics downgraded to Underweight from Neutral at Piper Jaffray
Piper Jaffray analyst David Amsellem downgraded Insys Therapeutics to Underweight and cut his price target for the shares to $4 from $5. The analyst sees "no basis in reality" for the company's guidance of relatively stable total sales in 2018 versus 2017 given the nature of the opioid crisis. Further, the weak rollout of Syndros "also does not inspire confidence" in the 2018 guidance, Amsellem tells investors in a research note.
08/10/18
PIPR
08/10/18
NO CHANGE
Target $4
PIPR
Underweight
Insys DOJ settlement does not remove downside risk, says Piper Jaffray
Piper Jaffray analyst David Amsellem says the settlement with the Department of Justice does not mean there isn't downside risk in shares of Insys Therapeutics. For a $600M market capitalization, investors are getting a sublingual form of buprenorphine that was "roundly rejected" by an FDA panel in May, a cannabidiol product that has yet to demonstrate proof-of-concept in a well-controlled trial, a product in Syndros that has minimal sales after approximately one year of active promotion, and a declining asset in Subsys that has limited profitability, Amsellem tells investors in a research note following Insys' Q2 results. The analyst does not believe the shares are "adequately risk-adjusted." He reiterates an Underweight rating on Insys with a $4 price target.
LIVN LivaNova
$102.32

1.14 (1.13%)

11/20/18
JEFF
11/20/18
NO CHANGE
Target $150
JEFF
Buy
CMS proposal opens 'massive new market' for LivaNova, says Jefferies
The Centers for Medicare & Medicaid Services proposed to extend coverage for vagus nerve stimulation in treatment-resistant depression with the caveat that LivaNova must conduct a double-blind, randomized, placebo-controlled trial with one year follow-up, Jefferies analyst Raj Denhoy tells investors in a research note. However, should the company show positive interim results, coverage will then move to a registry, adds the analyst. He points out that the CMS also agreed to cover replacement devices in existing patients. While there is work to do, CMS agreeing to pay for treatment-resistant depression "opens the door to a massive new market" for LivaNova, says Denhoy. He arrives at a $50 per share for the value of treatment-resistant depression under the plan outlined by CMS. With the base business worth about $100 a share, the analyst continues to value LivaNova at $150 per share. He keeps a Buy rating on the name
11/27/18
UBSW
11/27/18
INITIATION
UBSW
Neutral
LivaNova initiated with a Neutral at UBS
UBS analyst Matthew Taylor initiated LivaNova with a Neutral rating and $105 price target.
11/20/18
PIPR
11/20/18
NO CHANGE
Target $145
PIPR
Overweight
LivaNova price decline on CMS disclosure on TRD overdone, says Piper Jaffray
Piper Jaffray analyst Matt O'Brien kept his Overweight rating and $145 price target on LivaNova after the company's call to address the decision by U.S. Centers for Medicare & Medicaid Services regarding its National Coverage Determination for the LivaNova Vagus Nerve Stimulation Therapy System for Treatment-Resistant Depression, or TRD. The analyst states that his long-term TRD thesis is "largely unchanged", noting that the price decline today is likely overdone "given the potential for broad-based approval in 2020 or earlier assuming positive trial endpoints".
11/20/18
STFL
11/20/18
NO CHANGE
Target $140
STFL
Buy
LivaNova CMS proposal 'directionally positive,' says Stifel
After CMS presented its "long-awaited" proposal decision memo for LivaNova's VNS Therapy for treatment resistant depression, Stifel analyst Rick Wise said the proposal contains some "frustrating elements," such as CMS requesting an additional randomized trial that potentially could delay full-Medicare coverage at least 12-24 months. However, the proposal is "still directionally positive," said Wise, who is encouraged that CMS did not close the door on VNS Therapy coverage, replacement for existing VNS patients will be covered and the path forward for ultimate coverage is now clearer. The analyst maintains a Buy rating and $140 price target on LivaNova shares.
MNK Mallinckrodt
$24.16

0.36 (1.51%)

11/27/18
JEFF
11/27/18
NO CHANGE
Target $35
JEFF
Buy
Atlantis study unlikely to impact Mallinckrodt script trends, says Jefferies
Mallinckrodt shares sold off 8% yesterday on a delayed circulation of results from the Atlantis trial, a randomized prospective study aimed at examining safety and efficacy of Acthar in treating pediatric patients with nephrotic syndrome, Jefferies analyst Anthony Petrone tells investors in a research note. The trial was stopped at interim as the majority of participants treated with Acthar experienced a relapse within 23 days, which was similar to the control arm, says the analyst. Hence, Acthar showed no benefit at preventing relapse of nephrotic syndrome in pediatric patients, Petrone notes. The analyst says he confirmed that the Atlantis study was an investigator-led study and was not officially sponsored by the company. He adds that Acthar use in pediatric nephrotic syndrome is minimal and that several other NS study readouts "point toward efficacy in refractive patients." As such, Petrone does not see the Atlantis results as being pivotal in impacting near-term prescription trends or as an indicator of future readouts to come in 2019. He keeps a Buy rating on Mallinckrodt with a $35 price target.
11/27/18
ADAM
11/27/18
NO CHANGE
Target $40
ADAM
Buy
Citron tweet on Mallinckrodt an 'Acthar nothingburger,' says Canaccord
Canaccaord analyst Dewey Steadman tells investors in a research note that yesterday's tweet by Citron Research with a link to an article in Clinical Journal of the American Society of Nephrology that showed Mallinckrodt's Acthar showed little efficacy in pediatric nephrotic syndrome patients is "essentially old news" that is not relevant to the current Acthar franchise. The analyst, who called the news "an Acthar nothingburger," sees robust data in six indications as key drivers to tamp down over-reactions to non-important data reads. The analyst reiterates a Buy rating on Mallinckrodt with a $40 price target and sees an "even better" entry point into the story at these levels.
11/23/18
ADAM
11/23/18
NO CHANGE
Target $40
ADAM
Buy
Mallinckrodt Acthar franchise not impacted by HHS opinion, says Canaccord
Canaccord analyst Dewey Steadman noted Mallinckrodt received an advisory opinion from the HHS denying what appeared to be the company's request to distribute free vials of Acthar to hospitals to encourage use in West syndrome and infantile spasms. The analyst views the opinion as clearly anti-patient and not particularly negative to the IS sub-franchise within Acthar, as the current distribution status quo appears to have been maintained. He sees the weakness in the shares as a chance to build a position in the name. Steadman reiterated his Buy rating and $40 price target on Mallinckrodt shares.
11/19/18
WELS
11/19/18
NO CHANGE
Target $27
WELS
Market Perform
OIG response to Mallinckrodt's Acthar proposal a negative, says Wells Fargo
The Office of the Inspector General of the Department of Health and Human Services has advised Mallinckrodt (MNK) that the proposed patient access program for Acthar in hospitals would "present more than a minimal risk of fraud and abuse under the anti-kickback statute," Wells Fargo analyst David Maris tells investors in a research note. While not a setback to current Acthar sales, this is a negative outcome in Mallinckrodt's efforts to expand access to the drug, says the analyst. He believes the OIG opinion effectively states that if Mallinckrodt gives Acthar to hospitals for free for a chronic syndrome, and then will provide it for free only to those patients when discharged whose insurance won't pay for it, then the company is effectively giving away a product to help get those with commercial insurance to pay for it when out of the hospital. Maris thinks Mallinckrodt's Acthar faces a "challenging environment" with HHS and OIG. He keeps a Market Perform rating on the shares with a $27 price target.
MDT Medtronic
$98.73

1.21 (1.24%)

11/27/18
BMOC
11/27/18
NO CHANGE
Target $108
BMOC
Outperform
Medtronic leveraging successful diabetes pump business, says BMO Capital
BMO Capital analyst Joanne Wuensch kept her Outperform rating and $108 price target on Medtronic after her Diabetes Dynamos series with the company, saying the discussion suggests that it is "leveraging its successful pump business to develop an all-inclusive treatment paradigm." The analyst notes that beyond the tough annualized comps in the second half of 2019, Medtronic is positioned well entering FY20 "with a clear path towards a new MiniMed 690G pump platform, a wave of new continuous glucose monitoring upgrades, and a total solution platform that reduces the cognitive burden and barrier of adoption." Wuensch is positive on the company's product portfolio, healthy cash flow, dividend yield, and valuation.
11/26/18
WELS
11/26/18
INITIATION
Target $22
WELS
Outperform
Axonics initiated with an Outperform at Wells Fargo
Wells Fargo analyst Larry Biegelsen started Axonics (AXNX) with an Outperform rating and $22 price target. Historically, the sacral neuromodulationcategory has been a one-player market but he believes Axonics - when FDA approved - will be able to take share from Medtronic (MDT) and help catalyze broader SNM market growth and penetration.
11/26/18
MSCO
11/26/18
INITIATION
Target $21
MSCO
Overweight
Axonics initiated with an Overweight at Morgan Stanley
Morgan Stanley analyst David Lewis started Axonics (AXNX) with an Overweight rating and $21 price target, citing his view that the company can take material share in the sacral neuromodulation market with its "innovative" r-SNM system. The Axonics device is uniquely positioned to disrupt the only player in the market, Medtronic (MDT), with advantages that include MRI-compatibility, better battery life, smaller implant size and an easier user interface, Lewis tells investors.
11/27/18
UBSW
11/27/18
INITIATION
UBSW
Buy
Medtronic initiated with a Buy at UBS
UBS analyst Matthew Taylor initiated Medtronic with a Buy rating and $112 price target, calling the stock a Top Buy for Quality/FCF/Value. Taylor said "Looking forward, we think MSD comp adjusted growth continues based on our analysis of UBS Evidence Lab data and doctor checks."
NVS Novartis
$91.55

0.03 (0.03%)

11/26/18
COWN
11/26/18
UPGRADE
COWN
Outperform
Novartis upgraded to Outperform from Market Perform at Cowen
11/26/18
COWN
11/26/18
UPGRADE
Target $100
COWN
Outperform
Cowen upgrades Novartis to Outperform, calls stock a best idea for 2019
As reported previously, Cowen analyst Steven Scala upgraded Novartis to Outperform from Market Perform. The analyst called it his Best Idea for 2019 as the company has transformed its business to deliver big potential new drugs with upside potential. He also cites aggressive management and the recent underperformance of the shares. Scala raised his price target to $100 from $90 on Novartis shares.
11/19/18
GSCO
11/19/18
UPGRADE
GSCO
Conviction Buy
Novartis upgraded to Conviction Buy from Neutral at Goldman Sachs
Goldman Sachs analyst Katherine Alexakis Friday evening upgraded Novartis to Buy from Neutral and added the shares to her firm's Conviction List. The analyst believes Novartis is entering a period of sustained sales growth, driven by a "reinvigorated" pharma business, recently launched products and late-stage pipeline assets. Alexakis sees a "more focused company with higher returns and growth, meriting a premium valuation to large-cap EU pharma."
11/26/18
11/26/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. AT&T (T) upgraded to Neutral from Sell at MoffettNathanson analyst Craig Moffett citing valuation. 2. Cognizant (CTSH) upgraded to Buy from Neutral at Goldman Sachs with analyst James Schneider saying Improving revenue growth brings prospects for a stock "re-rating." 3. Regions Financial (RF) upgraded to Overweight from Neutral at JPMorgan with analyst Vivek Juneja saying he expects the company to benefit from commercial and industrial loan growth, low deposit beta and improved efficiency. 4. Intuit (INTU) upgraded to Outperform from Sector Perform at RBC Capital with analyst Ross MacMillan citing the findings from his most recent survey of tax filers which suggests that "do-it-yourself" tax preparation should gain share from assisted filings as a result of the latest tax code changes. 5. Novartis (NVS) upgraded to Outperform from Market Perform at Cowen with analyst Steven Scala saying he called it his Best Idea for 2019 as the company has transformed its business to deliver big potential new drugs with upside potential. He also cites aggressive management and the recent underperformance of the shares. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
OVID Ovid Therapeutics
$4.09

0.02 (0.49%)

08/06/18
PIPR
08/06/18
NO CHANGE
Target $20
PIPR
Overweight
Ovid Therapeutics shares should recover from here, says Piper Jaffray
Piper Jaffray analyst Tyler Van Buren attributes Ovid Therapeutics' selloff to the lack of statistical significance on the domain-based endpoints in the Phase 2 STARS trial, but he believes the shares will recover from these levels as appreciation for the just-reported data grows and as the report of OV935 proof of concept dEE data near year-end approaches. The analyst, who thinks the dEE data has "exciting potential," keeps an Overweight rating and $20 price target on Ovid shares, which are down 35% to $6.20 in afternoon trading.
11/15/18
CANT
11/15/18
INITIATION
Target $10
CANT
Overweight
Ovid Therapeutics initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Charles Duncan last night initiated coverage of Ovid Therapeutics with an Overweight rating and $10 price target. The analyst rolled out coverage on five Neuro-Innovator companies, focusing on "innovative technologies that can lead to breakthrough and disruptive treatments." He believes all five companies have "growth potential that exceeds current valuations, over time."
08/10/18
PIPR
08/10/18
NO CHANGE
Target $20
PIPR
Overweight
Piper sees value coming back into Ovid shares after pullback
Shares of Ovid Therapeutics have pulled back following the recent Angelman's data release, but investors underappreciate the exploratory nature of what was the first study of its kind, Piper Jaffray analyst Tyler Van Buren tells investors in a research note. Further, he believes the FDA will give flexibility in designing a registrational program for OV101 given the lack of treatments option and the significant unmet needs that exists for these patients. The analyst maintains an Overweight rating on Ovid with a $20 price target, believing share value will accrue as investors get a greater appreciation for the OV101 program and opportunity.
11/14/18
CANT
11/14/18
INITIATION
Target $10
CANT
Overweight
Ovid Therapeutics initiated with an Overweight at Cantor Fitzgerald
Price target $10.
RICOY Ricoh
$0.00

(0.00%)

07/02/18
GSCO
07/02/18
UPGRADE
GSCO
Neutral
Ricoh upgraded to Neutral from Sell at Goldman Sachs
Goldman Sachs analyst Satoru Ogawa upgraded Ricoh to Neutral with an increased price target of 1,000 yen. Ricoh's earnings have improved during the past year amid structural reforms and the share price downside is now limited, the analyst contends.
SUPN Supernus
$48.83

1.51 (3.19%)

09/18/18
09/18/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Walmart (WMT) initiated with an Outperform at BMO Capital while Target (TGT) was initiated with a Market Perform. 2. Apache (APA) initiated with an Overweight at Stephens. 3. Supernus (SUPN) initiated with a Buy at Mizuho. 4. Transocean (RIG) initiated with a Buy at BTIG. 5. Noble initiated with a Neutral at BTIG. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/18/18
MZHO
09/18/18
INITIATION
Target $61
MZHO
Buy
Mizuho starts Supernus with Buy rating, $61 price target
Mizuho analyst Irina Koffler last night initiated coverage of Supernus Pharmaceuticals with a Buy rating and $61 price target. The company, with a "promising" pipeline that can drive growth through pending Trokendi XR competition in migraine, is well positioned in an attractive market, Koffler told investors in a research note.
09/17/18
MZHO
09/17/18
INITIATION
Target $61
MZHO
Buy
Supernus initiated with a Buy at Mizuho
Mizuho initiated Supernus with a Buy and $61 price target.
10/29/18
MZHO
10/29/18
NO CHANGE
Target $61
MZHO
Buy
Supernus risk/reward favorable into data catalyst, says Mizuho
Mizuho analyst Irina Koffler views Supernus Pharmaceuticals' risk/reward as favorable into the Q4 Phase III adult attention-deficit/hyperactivity disorder read-out for SPN-812. The Phase IIb efficacy data for SPN-812 was similar to approved drugs, and the Phase III study design did not introduce any novel changes to a well-established blueprint for approval, Koffler tells investors in a research note. She reiterates a Buy rating on Supernus with a $61 price target.
WTKWY Wolters Kluwer
$0.00

(0.00%)

TODAY'S FREE FLY STORIES

WFC

Wells Fargo

$53.80

0.3 (0.56%)

, AAPL

Apple

$265.73

3.07 (1.17%)

10:01
11/16/19
11/16
10:01
11/16/19
10:01
Periodicals
Berkshire Hathaway inactive with record cash hoard, Barron's says »

Berkshire Hathaway…

WFC

Wells Fargo

$53.80

0.3 (0.56%)

AAPL

Apple

$265.73

3.07 (1.17%)

OXY

Occidental Petroleum

$38.94

1.18 (3.13%)

BRK.B

Berkshire Hathaway

$219.74

0.38 (0.17%)

BRK.A

Berkshire Hathaway

$329,361.11

266.11 (0.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Jan

DIS

Disney

$144.63

-2.56 (-1.74%)

09:43
11/16/19
11/16
09:43
11/16/19
09:43
Periodicals
Disney+ may not be able to hold onto huge number of subs, Barron's says »

While Disney's (DIS)…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDT

Medtronic

$112.11

2.9 (2.66%)

09:27
11/16/19
11/16
09:27
11/16/19
09:27
Periodicals
Medtronic shares 'could rise even more,' Barron's says »

Barron's recommended…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

BR

Broadridge

$119.80

0.485 (0.41%)

09:18
11/16/19
11/16
09:18
11/16/19
09:18
Periodicals
Broadridge a defensive name that can withstand slowdown, Barron's says »

Broadridge Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MCD

McDonald's

$193.95

-0.02 (-0.01%)

, MDT

Medtronic

$112.11

2.9 (2.66%)

09:07
11/16/19
11/16
09:07
11/16/19
09:07
Periodicals
Barron's suggests dividend stocks for retirement savers »

In this week's…

MCD

McDonald's

$193.95

-0.02 (-0.01%)

MDT

Medtronic

$112.11

2.9 (2.66%)

KO

Coca-Cola

$52.67

0.03 (0.06%)

PRU

Prudential

$93.61

0.82 (0.88%)

SYF

Synchrony

$37.05

0.34 (0.93%)

KEY

KeyCorp

$18.96

0.1 (0.53%)

T

AT&T

$39.49

0.53 (1.36%)

AMGN

Amgen

$220.84

2.29 (1.05%)

CSCO

Cisco

$45.10

0.18 (0.40%)

RCL

Royal Caribbean

$117.91

2.69 (2.33%)

MRK

Merck

$84.89

0.33 (0.39%)

JNJ

Johnson & Johnson

$134.97

3.99 (3.05%)

MSFT

Microsoft

$149.95

1.89 (1.28%)

JPM

JPMorgan

$129.51

0.83 (0.65%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

  • 18

    Nov

  • 19

    Nov

  • 19

    Nov

  • 20

    Nov

  • 21

    Nov

  • 22

    Nov

  • 02

    Dec

  • 04

    Dec

  • 07

    Dec

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 10

    Dec

  • 10

    Dec

  • 14

    Jan

  • 21

    Jan

  • 23

    Jan

  • 24

    Jan

  • 24

    Jan

  • 29

    Jan

  • 05

    Feb

  • 12

    Feb

  • 14

    Mar

AMZN

Amazon.com

$1,737.49

-17.22 (-0.98%)

, MSFT

Microsoft

$149.95

1.89 (1.28%)

08:54
11/16/19
11/16
08:54
11/16/19
08:54
On The Fly
Week in review: How Trump's policies moved stocks »

Catch up on the top…

AMZN

Amazon.com

$1,737.49

-17.22 (-0.98%)

MSFT

Microsoft

$149.95

1.89 (1.28%)

AAPL

Apple

$265.73

3.07 (1.17%)

CI

Cigna

$196.08

6.41 (3.38%)

CNC

Centene

$57.57

2.91 (5.32%)

CVS

CVS Health

$74.27

1.34 (1.84%)

HUM

Humana

$335.43

17.48 (5.50%)

UNH

UnitedHealth

$269.44

13.68 (5.35%)

WCG

WellCare

$312.01

10.155 (3.36%)

HNT

Health Net

$0.00

(0.00%)

MOH

Molina Healthcare

$129.60

7.3 (5.97%)

ANTM

Anthem

$298.18

16.14 (5.72%)

HCA

HCA Healthcare

$137.98

3.51 (2.61%)

CYH

Community Health

$3.12

0.25 (8.71%)

LPNT

LifePoint

$0.00

(0.00%)

UHS

Universal Health

$144.30

3.13 (2.22%)

THC

Tenet

$30.55

1.08 (3.66%)

GM

General Motors

$36.87

0.07 (0.19%)

FCAU

Fiat Chrysler

$16.02

0.04 (0.25%)

TM

Toyota

$144.29

1.16 (0.81%)

F

Ford

$8.96

0.16 (1.82%)

HMC

Honda

$28.99

0.155 (0.54%)

VWAGY

Volkswagen

$0.00

(0.00%)

BMWYY

BMW

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 19

    Nov

  • 20

    Nov

  • 20

    Nov

  • 22

    Nov

  • 04

    Dec

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 13

    Dec

  • 04

    Feb

  • 06

    Feb

MDCO

The Medicines Co.

$51.92

1.03 (2.02%)

04:55
11/16/19
11/16
04:55
11/16/19
04:55
Conference/Events
Roth Capital pharmaceuticals analysts to hold a luncheon »

Analysts host Dr. John…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Nov

CVET

Covetrus

$14.93

1.44 (10.67%)

18:41
11/15/19
11/15
18:41
11/15/19
18:41
Hot Stocks
Covetrus CEO: We're a leader in the humanization of pets »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMCSK

Comcast

$0.00

(0.00%)

, CMCSA

Comcast

$44.54

-0.93 (-2.05%)

18:02
11/15/19
11/15
18:02
11/15/19
18:02
Hot Stocks
Viacom extends cable deal for 'The Office' through 2025 »

Viacom (VIA) announced…

CMCSK

Comcast

$0.00

(0.00%)

CMCSA

Comcast

$44.54

-0.93 (-2.05%)

VIAB

Viacom

$23.07

0.59 (2.62%)

VIA

Viacom

$26.59

1.28 (5.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

CWK

Cushman & Wakefield

$19.10

0.1 (0.53%)

17:48
11/15/19
11/15
17:48
11/15/19
17:48
Hot Stocks
Cushman & Wakefield CEO sells 84.6K share of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

LMT

Lockheed Martin

$393.52

3.305 (0.85%)

17:39
11/15/19
11/15
17:39
11/15/19
17:39
Hot Stocks
Lockheed Martin awarded maximum $3.33B Air Force contract »

Lockheed Martin has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ESCA

Escalade

$10.90

-0.09 (-0.82%)

17:38
11/15/19
11/15
17:38
11/15/19
17:38
Hot Stocks
Escalade CEO Fetherman to retire »

Escalade announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CZR

Caesars

$12.96

0.1 (0.78%)

, ERI

Eldorado Resorts

$52.10

0.93 (1.82%)

17:38
11/15/19
11/15
17:38
11/15/19
17:38
Hot Stocks
Eldorado, Caesars stockholders approve Eldorado acquisition of Caesars »

Eldorado Resorts (ERI)…

CZR

Caesars

$12.96

0.1 (0.78%)

ERI

Eldorado Resorts

$52.10

0.93 (1.82%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

EGRX

Eagle Pharmaceuticals

$57.24

0.55 (0.97%)

17:15
11/15/19
11/15
17:15
11/15/19
17:15
Syndicate
Breaking Syndicate news story on Eagle Pharmaceuticals »

Eagle Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FN

Fabrinet

$60.82

0.84 (1.40%)

17:11
11/15/19
11/15
17:11
11/15/19
17:11
Hot Stocks
Fabrinet President Gill sells 12.9K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

TEUM

Pareteum

$0.38

-0.0209 (-5.21%)

17:05
11/15/19
11/15
17:05
11/15/19
17:05
Hot Stocks
Pareteum receives noncompliance notice from Nasdaq »

Pareteum announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HEXO

Hexo

$1.78

-0.1 (-5.32%)

17:00
11/15/19
11/15
17:00
11/15/19
17:00
Hot Stocks
Hexo was cannabis was being grown in unlicensed space at Niagara site »

HEXO Corp provided…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMGN

Amgen

$220.84

2.29 (1.05%)

, CELG

Celgene

$110.02

-0.01 (-0.01%)

16:57
11/15/19
11/15
16:57
11/15/19
16:57
Hot Stocks
Bristol-Myers gets FTC clearance for Celgene acquisition »

Bristol-Myers Squibb…

AMGN

Amgen

$220.84

2.29 (1.05%)

CELG

Celgene

$110.02

-0.01 (-0.01%)

BMY

Bristol-Myers

$58.61

0.11 (0.19%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

  • 04

    Dec

  • 07

    Dec

  • 25

    Mar

  • 04

    Apr

RAVE

Rave Restaurant

$1.44

-0.79 (-35.43%)

16:47
11/15/19
11/15
16:47
11/15/19
16:47
Hot Stocks
BBRC Asset Management reports 6.6% passive stake in Rave Restaurant »

BBRC Asset Management …

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CHAP

Chaparral Energy

$0.89

-0.0521 (-5.52%)

16:46
11/15/19
11/15
16:46
11/15/19
16:46
Hot Stocks
Chaparral Energy receives continued listing standard notice from NYSE »

Chaparral Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:45
11/15/19
11/15
16:45
11/15/19
16:45
General news
Breaking General news story  »

San Francisco Federal…

16:45
11/15/19
11/15
16:45
11/15/19
16:45
General news
Breaking General news story  »

San Francisco Federal…

CI

Cigna

$196.08

6.41 (3.38%)

, CNC

Centene

$57.57

2.91 (5.32%)

16:41
11/15/19
11/15
16:41
11/15/19
16:41
On The Fly
Fly Intel: Wall Street's top stories for Friday »

Stocks closed out the…

CI

Cigna

$196.08

6.41 (3.38%)

CNC

Centene

$57.57

2.91 (5.32%)

CVS

CVS Health

$74.27

1.34 (1.84%)

HUM

Humana

$335.43

17.48 (5.50%)

UNH

UnitedHealth

$269.44

13.68 (5.35%)

WCG

WellCare

$312.01

10.155 (3.36%)

HNT

Health Net

$0.00

(0.00%)

MOH

Molina Healthcare

$129.60

7.3 (5.97%)

ANTM

Anthem

$298.18

16.14 (5.72%)

HCA

HCA Healthcare

$137.98

3.51 (2.61%)

CYH

Community Health

$3.12

0.25 (8.71%)

LPNT

LifePoint

$0.00

(0.00%)

UHS

Universal Health

$144.30

3.13 (2.22%)

NVDA

Nvidia

$204.12

-5.76 (-2.74%)

AMZN

Amazon.com

$1,739.33

-15.38 (-0.88%)

MSFT

Microsoft

$149.95

1.89 (1.28%)

UAA

Under Armour

$17.78

0.65 (3.79%)

UA

Under Armour

$15.97

0.41 (2.64%)

AMRN

Amarin

$23.99

2.5 (11.63%)

JNJ

Johnson & Johnson

$134.97

3.99 (3.05%)

GOOG

Alphabet

$1,334.01

21.82 (1.66%)

GOOGL

Alphabet Class A

$1,333.33

23.54 (1.80%)

ORCL

Oracle

$56.43

0.33 (0.59%)

RH

RH

$188.73

13.535 (7.73%)

QGEN

Qiagen

$40.56

3.255 (8.73%)

FTCH

Farfetch

$9.66

2.17 (28.97%)

THC

Tenet

$30.55

1.08 (3.66%)

TORC

resTORbio

$1.10

-6.83 (-86.13%)

ACB

Aurora Cannabis

$2.72

-0.57 (-17.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 19

    Nov

  • 19

    Nov

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 22

    Nov

  • 04

    Dec

  • 07

    Dec

  • 09

    Dec

  • 09

    Dec

  • 13

    Dec

  • 28

    Dec

  • 06

    Jan

  • 21

    Jan

  • 06

    Feb

NYT

New York Times

$31.60

0.44 (1.41%)

16:41
11/15/19
11/15
16:41
11/15/19
16:41
Hot Stocks
New York Times CEO sells 66,000 class A common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

WEX

Wex

$200.52

4.61 (2.35%)

16:41
11/15/19
11/15
16:41
11/15/19
16:41
Hot Stocks
Wex director Morris sells 3K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.